Research Smad2 and Smad6 as predictors of overall survival in oral squamous cell carcinoma patients
Autor(a) principal: | |
---|---|
Data de Publicação: | 2010 |
Outros Autores: | , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://dx.doi.org/10.1186/1476-4598-9-106 http://repositorio.unifesp.br/handle/11600/32543 |
Resumo: | Background: To test if the expression of Smad1-8 mRNAs were predictive of survival in patients with oral squamous cell carcinoma (SCC).Patients and Methods: We analyzed, prospectively, the expression of Smad1-8, by means of Ribonuclease Protection Assay in 48 primary, operable, oral SCC. in addition, 21 larynx, 10 oropharynx and 4 hypopharynx SCC and 65 matched adjacent mucosa, available for study, were also included. for survival analysis, patients were categorized as positive or negative for each Smad, according to median mRNA expression. We also performed real-time quantitative PCR (QRTPCR) to asses the pattern of TGF beta 1, TGF beta 2, TGF beta 3 in oral SCC.Results: Our results showed that Smad2 and Smad6 mRNA expression were both associated with survival in Oral SCC patients. Cox Multivariate analysis revealed that Smad6 positivity and Smad2 negativity were both predictive of good prognosis for oral SCC patients, independent of lymph nodal status (P = 0.003 and P = 0.029, respectively). in addition, simultaneously Smad2(-) and Smad6(+) oral SCC group of patients did not reach median overall survival (mOS) whereas the mOS of Smad2(+)/Smad6(-) subgroup was 11.6 months (P = 0.004, univariate analysis). Regarding to TGF beta isoforms, we found that Smad2 mRNA and TGF beta 1 mRNA were inversely correlated (p = 0.05, R = -0.33), and that seven of the eight TGF beta 1(+) patients were Smad2(-). in larynx SCC, Smad7(-) patients did not reach mOS whereas mOS of Smad7(+) patients were only 7.0 months (P = 0.04). No other correlations were found among Smad expression, clinico-pathological characteristics and survival in oral, larynx, hypopharynx, oropharynx or the entire head and neck SCC population.Conclusion: Smad6 together with Smad2 may be prognostic factors, independent of nodal status in oral SCC after curative resection. the underlying mechanism which involves aberrant TGF beta signaling should be better clarified in the future. |
id |
UFSP_bf16003c84a6f4e64cb16948da97d6c2 |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br/:11600/32543 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Research Smad2 and Smad6 as predictors of overall survival in oral squamous cell carcinoma patientsBackground: To test if the expression of Smad1-8 mRNAs were predictive of survival in patients with oral squamous cell carcinoma (SCC).Patients and Methods: We analyzed, prospectively, the expression of Smad1-8, by means of Ribonuclease Protection Assay in 48 primary, operable, oral SCC. in addition, 21 larynx, 10 oropharynx and 4 hypopharynx SCC and 65 matched adjacent mucosa, available for study, were also included. for survival analysis, patients were categorized as positive or negative for each Smad, according to median mRNA expression. We also performed real-time quantitative PCR (QRTPCR) to asses the pattern of TGF beta 1, TGF beta 2, TGF beta 3 in oral SCC.Results: Our results showed that Smad2 and Smad6 mRNA expression were both associated with survival in Oral SCC patients. Cox Multivariate analysis revealed that Smad6 positivity and Smad2 negativity were both predictive of good prognosis for oral SCC patients, independent of lymph nodal status (P = 0.003 and P = 0.029, respectively). in addition, simultaneously Smad2(-) and Smad6(+) oral SCC group of patients did not reach median overall survival (mOS) whereas the mOS of Smad2(+)/Smad6(-) subgroup was 11.6 months (P = 0.004, univariate analysis). Regarding to TGF beta isoforms, we found that Smad2 mRNA and TGF beta 1 mRNA were inversely correlated (p = 0.05, R = -0.33), and that seven of the eight TGF beta 1(+) patients were Smad2(-). in larynx SCC, Smad7(-) patients did not reach mOS whereas mOS of Smad7(+) patients were only 7.0 months (P = 0.04). No other correlations were found among Smad expression, clinico-pathological characteristics and survival in oral, larynx, hypopharynx, oropharynx or the entire head and neck SCC population.Conclusion: Smad6 together with Smad2 may be prognostic factors, independent of nodal status in oral SCC after curative resection. the underlying mechanism which involves aberrant TGF beta signaling should be better clarified in the future.Univ São Paulo, Disciplina Oncol, Dept Radiol, Fac Med,LIM 24,Hosp Clin, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Otorrinolaringol, São Paulo, BrazilHosp Heliopolis, Serv Cirurgia Cabeca & Pescoco, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Otorrinolaringol, São Paulo, BrazilWeb of ScienceFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)FAPESP: 02/01738-9Biomed Central LtdUniversidade de São Paulo (USP)Universidade Federal de São Paulo (UNIFESP)Hosp HeliopolisMangone, Flavia R. R.Walder, Fernando [UNIFESP]Maistro, SimonePasini, Fatima S.Lehn, Carlos N.Carvalho, Marcos B.Brentani, M. MitziSnitcovsky, IgorFederico, Miriam H. H. [UINIFESP]2016-01-24T13:59:41Z2016-01-24T13:59:41Z2010-05-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion10application/pdfhttp://dx.doi.org/10.1186/1476-4598-9-106Molecular Cancer. London: Biomed Central Ltd, v. 9, 10 p., 2010.10.1186/1476-4598-9-106WOS000279275100001.pdf1476-4598http://repositorio.unifesp.br/handle/11600/32543WOS:000279275100001engMolecular Cancerinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-08-07T17:06:38Zoai:repositorio.unifesp.br/:11600/32543Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-08-07T17:06:38Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.none.fl_str_mv |
Research Smad2 and Smad6 as predictors of overall survival in oral squamous cell carcinoma patients |
title |
Research Smad2 and Smad6 as predictors of overall survival in oral squamous cell carcinoma patients |
spellingShingle |
Research Smad2 and Smad6 as predictors of overall survival in oral squamous cell carcinoma patients Mangone, Flavia R. R. |
title_short |
Research Smad2 and Smad6 as predictors of overall survival in oral squamous cell carcinoma patients |
title_full |
Research Smad2 and Smad6 as predictors of overall survival in oral squamous cell carcinoma patients |
title_fullStr |
Research Smad2 and Smad6 as predictors of overall survival in oral squamous cell carcinoma patients |
title_full_unstemmed |
Research Smad2 and Smad6 as predictors of overall survival in oral squamous cell carcinoma patients |
title_sort |
Research Smad2 and Smad6 as predictors of overall survival in oral squamous cell carcinoma patients |
author |
Mangone, Flavia R. R. |
author_facet |
Mangone, Flavia R. R. Walder, Fernando [UNIFESP] Maistro, Simone Pasini, Fatima S. Lehn, Carlos N. Carvalho, Marcos B. Brentani, M. Mitzi Snitcovsky, Igor Federico, Miriam H. H. [UINIFESP] |
author_role |
author |
author2 |
Walder, Fernando [UNIFESP] Maistro, Simone Pasini, Fatima S. Lehn, Carlos N. Carvalho, Marcos B. Brentani, M. Mitzi Snitcovsky, Igor Federico, Miriam H. H. [UINIFESP] |
author2_role |
author author author author author author author author |
dc.contributor.none.fl_str_mv |
Universidade de São Paulo (USP) Universidade Federal de São Paulo (UNIFESP) Hosp Heliopolis |
dc.contributor.author.fl_str_mv |
Mangone, Flavia R. R. Walder, Fernando [UNIFESP] Maistro, Simone Pasini, Fatima S. Lehn, Carlos N. Carvalho, Marcos B. Brentani, M. Mitzi Snitcovsky, Igor Federico, Miriam H. H. [UINIFESP] |
description |
Background: To test if the expression of Smad1-8 mRNAs were predictive of survival in patients with oral squamous cell carcinoma (SCC).Patients and Methods: We analyzed, prospectively, the expression of Smad1-8, by means of Ribonuclease Protection Assay in 48 primary, operable, oral SCC. in addition, 21 larynx, 10 oropharynx and 4 hypopharynx SCC and 65 matched adjacent mucosa, available for study, were also included. for survival analysis, patients were categorized as positive or negative for each Smad, according to median mRNA expression. We also performed real-time quantitative PCR (QRTPCR) to asses the pattern of TGF beta 1, TGF beta 2, TGF beta 3 in oral SCC.Results: Our results showed that Smad2 and Smad6 mRNA expression were both associated with survival in Oral SCC patients. Cox Multivariate analysis revealed that Smad6 positivity and Smad2 negativity were both predictive of good prognosis for oral SCC patients, independent of lymph nodal status (P = 0.003 and P = 0.029, respectively). in addition, simultaneously Smad2(-) and Smad6(+) oral SCC group of patients did not reach median overall survival (mOS) whereas the mOS of Smad2(+)/Smad6(-) subgroup was 11.6 months (P = 0.004, univariate analysis). Regarding to TGF beta isoforms, we found that Smad2 mRNA and TGF beta 1 mRNA were inversely correlated (p = 0.05, R = -0.33), and that seven of the eight TGF beta 1(+) patients were Smad2(-). in larynx SCC, Smad7(-) patients did not reach mOS whereas mOS of Smad7(+) patients were only 7.0 months (P = 0.04). No other correlations were found among Smad expression, clinico-pathological characteristics and survival in oral, larynx, hypopharynx, oropharynx or the entire head and neck SCC population.Conclusion: Smad6 together with Smad2 may be prognostic factors, independent of nodal status in oral SCC after curative resection. the underlying mechanism which involves aberrant TGF beta signaling should be better clarified in the future. |
publishDate |
2010 |
dc.date.none.fl_str_mv |
2010-05-12 2016-01-24T13:59:41Z 2016-01-24T13:59:41Z |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1186/1476-4598-9-106 Molecular Cancer. London: Biomed Central Ltd, v. 9, 10 p., 2010. 10.1186/1476-4598-9-106 WOS000279275100001.pdf 1476-4598 http://repositorio.unifesp.br/handle/11600/32543 WOS:000279275100001 |
url |
http://dx.doi.org/10.1186/1476-4598-9-106 http://repositorio.unifesp.br/handle/11600/32543 |
identifier_str_mv |
Molecular Cancer. London: Biomed Central Ltd, v. 9, 10 p., 2010. 10.1186/1476-4598-9-106 WOS000279275100001.pdf 1476-4598 WOS:000279275100001 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Molecular Cancer |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
10 application/pdf |
dc.publisher.none.fl_str_mv |
Biomed Central Ltd |
publisher.none.fl_str_mv |
Biomed Central Ltd |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
biblioteca.csp@unifesp.br |
_version_ |
1814268389898584064 |